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Elucidating the Association Between Depressive Symptoms, Coronary
Heart Disease, and Stroke in Black and White Adults: The REasons for
Geographic And Racial Differences in Stroke (REGARDS) Study
Nathalie Moise, MD, MS; Yulia Khodneva, MD, PhD; Joshua Richman, MD, PhD; Daichi Shimbo, MD, MS; Ian Kronish, MD, MPH;
Monika M. Safford, MD
Background-—Depression is a relapsing and remitting disease. Prior studies on the association between depressive symptoms and
incident cardiovascular disease (CVD) have been limited by single measurements, and few if any have examined both incident
coronary heart disease and stroke in a large biracial national cohort. We aimed to assess whether time-dependent depressive
symptoms conferred increased risk of incident CVD.
Methods and Results-—Between 2003 to 2007, 22 666 black and white participants (aged ≥45 years) without baseline CVD in the
REasons for Geographic And Racial Differences in Stroke (REGARDS) study were recruited. Cox proportional hazards regression
analyses assessed the association between up to 3 measurements of elevated depressive symptoms (4-item Center for
Epidemiologic Studies Depression Scale score ≥4) and incident coronary heart disease, stroke, and CVD death adjusting for age,
sex, region, income, health insurance, education, blood pressure, cholesterol, medication, obesity, diabetes mellitus, kidney
disease, C-reactive protein, corrected QT interval, atrial fibrillation, left ventricular hypertrophy, smoking, alcohol, physical
inactivity, medication adherence, and antidepressant use. The participants’ average age was 63.4 years, 58.8% were female, and
41.7% black. Time-varying depressive symptoms were significantly associated with CVD death (adjusted hazard ratio 1.30, 95% CI
1.04–1.63), with a trend toward significance for fatal and nonfatal stroke (adjusted hazard ratio 1.26, 95% CI 0.99–1.60) but not
fatal and nonfatal coronary heart disease (adjusted hazard ratio 1.11, 95% CI 0.89–1.38). Race did not moderate the association
between depressive symptoms and CVD.
Conclusions-—Proximal depressive symptoms were associated with incident fatal and nonfatal stroke and CVD death even
after controlling for multiple explanatory factors, further supporting the urgent need for timely management of depressive
symptoms. ( J Am Heart Assoc. 2016;5:e003767 doi: 10.1161/JAHA.116.003767)
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A growing body of evidence suggests that depressivesymptoms may confer an increased risk for incident
cardiovascular disease (CVD).1–4 Nevertheless, few if any
previous studies have analyzed both coronary heart disease
(CHD) and stroke simultaneously in a large biracial national
sample, and almost all studies have been limited to single
measurements of depressive symptoms.5 Single measure-
ments do not account for the fact that depression is a
relapsing and remitting disease, and cumulative measure-
ments may be limited by selection bias through differential
loss to follow-up.
The mechanisms underlying the association between
depressive symptoms and CVD have proven difficult to fully
elucidate.4 Although successive meta-analyses have shown
that depressive symptoms increase the risk of incident CHD
and CHD death, with pooled hazard ratios (HRs) estimated at
1.6 and 1.8,2,3,6 there has been concern about incomplete
risk factor adjustment in the majority of studies included in
prior meta-analyses and limited use of time-dependent
variables.2 Similarly, although depressive symptoms have
been considered an inconsistent risk factor for incident
cerebrovascular disease,7–9 a recent meta-analysis found
pooled HRs of 1.5 and 1.6 for total and fatal stroke; again,
only 6 of 28 studies simultaneously controlled for alcohol,
body mass index, and smoking status, and 1 controlled for
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medication adherence.10 In addition to unmeasured con-
founders, research also remains inconsistent as to whether
race truly moderates the association between depressive
symptoms and incident CVD.11–14 Prior studies suggest that
racial and ethnic minorities face unique barriers to depression
treatment in the United States,15 and as such, it is unclear
how race and time-dependent depressive symptoms interact
to influence CVD events.
Given that time-varying analyses may better elucidate the
timing of the association between depressive symptoms and
CVD, the aim of this study was to assess whether time-varying
depressive symptoms confer increased risk of stroke and
CHD, adjusting for potential explanatory factors in a large
national diverse cohort. We secondarily sought to assess
whether depressive symptoms differentially predicted incident
stroke and CHD in black and white participants.
Methods
Study Procedures
Details of the REasons for Geographic And Racial Differ-
ences in Stroke (REGARDS) study have been described
previously.16 In brief, REGARDS is a national cohort study
of stroke incidence and cognitive decline in black and white
patients aged ≥45 years living in the United States and
stratified to reflect specific race, sex, and geographic
strata. CHD outcomes were ascertained from a REGARDS
ancillary study. Participants were recruited by mail using
commercially available lists of US residents, followed by a
telephone call and a subsequent home visit at which time
patients gave consent and were enrolled. Between January
2003 and October 2007, 30 183 black and white adults
were enrolled. Of these, 484 (1.6%) were lost to follow-up,
and 171 (0.6%) were missing baseline depressive symptom
measurements (Figure 1). Our current analysis was limited
to 22 666 participants without existing CVD at baseline
(6862 had stroke, CHD, peripheral vascular disease,
or aneurysm). The REGARDS study protocol was approved
by the institutional review boards of the participating
centers.
Baseline data were collected through computer-assisted
telephone interviews, an in-home examination, and self-
administered questionnaires. Trained research staff con-
ducted telephone interviews to collect demographic data
and education. Following telephone interview, patients had
an in-home visit during which physical measurements, a
resting electrocardiogram, medication inventory, phle-
botomy, and urine were collected. Medication use was
measured by self-report or pill bottle review during the in-
home visit.
Primary Outcomes
The primary outcomes for these analyses were (1) incident
CHD events, defined as definite or probable nonfatal or fatal
myocardial infarction or acute CHD death events; (2)
incident stroke events, defined as probable nonfatal or fatal
stroke; (3) incident CVD death, defined as death from CHD,
stroke, heart failure, sudden cardiac death, vascular pathol-
ogy, and other CVD causes. Living participants or their
proxies were followed up every 6 months by telephone, with
retrieval of medical records for reported hospitalizations or
physician visits. Data were collected on suspected stroke
events that required hospitalization and on physician eval-
uations for stroke-like symptoms detected using the Ques-
tionnaire for Verifying Stroke-Free Status.17 The adjudication
process validated stroke occurrence and classified events by
stroke “subtype” and severity using the National Institutes of
Health Stroke Scale. Stroke was defined as rapid onset of a
persistent neurological deficit attributable to an obstruction
or rupture of the arterial system (including stroke occurring
during a procedure such as angiograph or surgery) that
causes a deficit not known to be secondary to brain trauma;
that lasts >24 hours, unless death supervenes; and that has
a demonstrable lesion compatible with acute stroke on
computed tomography or magnetic resonance imaging.16,18
For CHD events, medical records were examined for the
presence of signs and symptoms of ischemia, cardiac
enzymes, electrocardiogram changes consistent with ische-
mia, or myocardial infarction based on the Minnesota code;
myocardial infarctions were adjudicated as being definite or
probable, based on published guidelines.19,20 Deaths were
detected by report of next of kin or through online services
(eg, Social Security Death Index) or the National Death
Index.16 Death certificates, medical records, and autopsy
reports were obtained to adjudicate cause of death and
cardiovascular outcomes.
Depressive Symptoms
The primary predictor was time-varying depressive symp-
toms. The 4-item Center for Epidemiologic Studies Depres-
sion Scale (CES-D) was used to assess the presence of
depressive symptoms. This scale asks participants to rate
the number of days over the past week in which they (1) felt
depressed, (2) felt lonely, (3) had crying spells, and (4) felt
sad. Response options included <1 day (no points), 1 to
2 days (1 point), 3 to 4 days (2 points), and 5 to 7 days (3
points). Cronbach’s a for the CES-D in the total sample was
0.80 and among black and white participants was 0.81 and
0.79, respectively. Elevated depressive symptoms were
defined as a summed score of ≥4.21 The reliability and
validity of the 4-item CES-D is similar to the original 20-item
DOI: 10.1161/JAHA.116.003767 Journal of the American Heart Association 2





























instrument.22 The CES-D was administered 3 times: (1)
during the initial telephone interview, (2) at 5 years after
baseline measurement, and (3) at 2 years after the second
measurement. CES-D scores measured after an end point or
after the end of follow-up were not eligible to be included in
the time-varying analysis.
Covariates
Demographic data included self-reported age, sex, race (black
or white), education (less than high school, high school
graduate, some college, and college graduate and higher),
annual income (less than $20 000, $20 000–$34 999,
Figure 1. Cohort flow diagram. Numbers of participants originally recruited for the REGARDS study, lost to
follow-up,missing baseline depressive symptoms, excluded from the analysis due to existing baseline CVD, and
in the final analysis. CES-D indicates Center for Epidemiologic Studies Depression Scale; CHD, coronary heart
disease; CVD, cardiovascular disease; REGARDS, REasons for Geographic And Racial Differences in Stroke.
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$35 000–$74 999, $75 000 and above), insurance status
(yes or no), and stroke region (“stroke belt,” defined as the
states of Alabama, Arkansas, Louisiana, Mississippi, Ten-
nessee, and the noncoastal regions within the states of North
Carolina, South Carolina, and Georgia; “stroke buckle,”
defined as coastal regions within the states of North Carolina,
South Carolina, and Georgia). Clinical CHD risk factors
included diabetes mellitus, defined as fasting blood glucose
≥126 mL/dL, random glucose >200 mL/dL, or oral hypo-
glycemic or insulin use; systolic and diastolic blood pressures
based on the average of 2 standardized blood pressure
measurements (continuous variables in mm Hg); body mass
index based on measured height and weight; albumin:
creatinine ratio; and high-density lipoprotein and total
cholesterol. We also assessed use of aspirin (yes or no),
statins (yes or no), and antihypertensive medications (yes or
no). Behavioral risk factors included (1) smoking status, based
on self-reported pack-years of cigarette smoking; (2) physical
inactivity, ascertained by asking, “How many times per week
do you engage in intense physical activity, enough to work up
a sweat?” with response options of “none,” “1 to 3 times per
week,” or “4 or more times per week”; (3) alcohol use,
ascertained by asking, “How many alcoholic beverages do you
drink?” and use based on National Institute on Alcohol Abuse
and Alcoholism classifications (none, moderate [1 drink per
day for women or 2 drinks per day for men], and heavy
[>1 drink per day for women and >2 drinks per day for
men])16; and (4) medication nonadherence, assessed with the
4-item Morisky Medication Adherence Scale (ranging from
0–4, with a score ≥1 indicating medication nonadherence).23
Potential mediators included high-sensitivity C-reactive
protein, QT intervals corrected for heart rate using the
formula QT+(1549[1(60/heart rate)]), and antidepressant
use (serotonin and norepinephrine reuptake inhibitors, selec-
tive serotonin reuptake inhibitors, tricyclic antidepressants;
yes or no).
Statistical Analyses
Baseline characteristics of participants with and without
elevated depressive symptoms at baseline were compared
using chi-square tests, Student t tests, and Kruskal–Wallis
tests, as appropriate.
Cox proportional hazards regression models were con-
structed to separately analyze the association between
depressive symptoms (CES-D score ≥4) and incident CHD,
incident stroke, and CVD death. The end date of follow-up for
this analysis was December 31, 2012. Follow-up time for each
participant was calculated from the date of the in-home visit
to the date of the earliest of the first CHD or stroke event,
death, the last telephone follow-up, or the end of follow-up.
Depressive symptoms were measured with the CES-D at
baseline and again at 5- and 7-year follow-up. In the analyses,
we considered depressive symptoms as a time-varying
exposure, with updates of exposure at 5- and 7-year follow-
up. Consequently, each participant contributed up to 3
measures of CES-D over follow-up. Adjusted modeling
proceeded in stages, with each model including additional
covariates. Model 1 adjusted for demographic factors,
including age, sex, region, income, health insurance, educa-
tion, and traditional CVD risk factors (systolic blood pressure;
total cholesterol; high-density lipoprotein-cholesterol; use of
aspirin, statins, or antihypertensives; body mass index;
logarithmically transformed albumin:creatinine ratio; and
diabetes status). Model 2 additionally adjusted for behavioral
CVD risk factors (pack-years of cigarette smoking, self-
reported alcohol use, physical inactivity, medication
nonadherence). Model 3 adjusted for other physiological
explanatory factors including logarithmically transformed
high-sensitivity C-reactive protein, antidepressant use, and
QT interval corrected for heart rate. Model 3 for stroke was
additionally adjusted for atrial fibrillation and left ventricular
hypertrophy. The analyses were conducted overall and were
stratified by race. We also conducted a formal test for
interaction with depressive symptoms by race in the fully
adjusted models. The proportionality assumption was tested
by assessing depressive symptoms by log of follow-up time
interactions and was satisfied for all end points.
Missing data in covariates were imputed using chained
equations, and final estimates were derived by bootstrapping
across the 5 imputed data sets. Among the 22 666 partic-
ipants, the following data were missing: 2768 (12%), income;
9 (0.03%), education; 22 (0.09%), health insurance; 831 (4%),
diabetes mellitus; 13 (0.06%), aspirin use; 61 (0.3%), statin
use; 61 (0.3%), antidepressant use; 242 (1%), antihypertension
medication use; 326 (1%), physical activity; 2415 (11%),
medication adherence; 146 (0.6%), body mass index; 908
(4%), cholesterol; 1027 (5%), high-density lipoprotein; 659
(3%), pack-years smoked; 60 (0.3%), systolic blood pressure;
1000 (4%), albumin:creatinine ratio; 296 (1%), corrected QT
interval; 1379 (6%), C-reactive protein. Analyses were con-
ducted using SAS software version 9.4 (SAS Institute) and
Stata version 12 (StataCorp).
Results
Participant Characteristics
Of the 22 666 eligible participants, 2267 (10.0%) had
elevated depressive symptoms at baseline (CES-D score
≥4). Overall, 73.7% of participants completed a second
measurement, and 59.9% completed a third measurement.
Of patients with elevated depressive symptoms at baseline,
39.2% and 37.5% had elevated depressive symptoms at the
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(n=20 399) P Value†
Sociodemographics
Age, y, meanSD 63.99.3 62.29.7 64.19.2 <0.001
Sex, n (%) <0.001
Female 13 321 (58.8) 1675 (73.9) 11 646 (57.1)
Race, n (%) <0.001
Black 9444 (41.7) 1183 (52.2) 8261 (40.5)
Education, n (%) <0.001
Less than high school 2466 (10.9) 484 (21.4) 1982 (9.7)
High school graduate 5718 (25.2) 692 (30.5) 5026 (24.7)
Some college 6127 (27.0) 592 (26.1) 5535 (27.1)
College graduate and higher 8343 (36.8) 498 (22.0) 7845 (38.5)
Annual household income, n (%) <0.001
Less than $20 000 3705 (16.3) 768 (33.9) 2937 (14.4)
$20 000 to $34 999 5314 (23.4) 573 (25.3) 4741 (23.2)
$35 000 to $74 999 6965 (30.7) 443 (19.5) 6522 (32.0)
$75 000 and above 3908 (17.2) 168 (7.4) 3740 (18.3)
Declined to report 2771 (12.2) 315 (13.9) 2456 (12.0)
No health insurance, n (%) 1642 (7.3) 307 (13.5) 1335 (6.6) <0.001
Region,‡ n (%) <0.001
Stroke belt 7832 (34.6) 850 (37.5) 6982 (34.2)
Stroke buckle 4776 (21.1) 533 (23.5) 4243 (20.8)
Not stroke belt or buckle 10 055 (44.4) 884 (39.0) 9171 (45.0)
Physiological risk factors
Body mass index, kg/m2, meanSD 29.36.2 30.57.0 29.26.1 <0.001
Diabetes mellitus,§ n (%) 4051 (18.6) 560 (25.6) 3491 (17.8) <0.001
Systolic blood pressure, mm Hg, meanSD 126.816.3 127.517.4 126.716.2 0.0370
Total cholesterol, mg/dL, meanSD 195.739.0 198.241.0 195.438.8 0.0014
High-density lipoprotein, mg/dL, meanSD 53.016.3 54.016.3 52.916.3 0.0027
QT interval, corrected for heart rate, ms, meanSD 406.022.2 408.021.8 405.822.2 <0.001
High-sensitivity C-reactive protein, mg/L, median (IQR) 2.2 [0.9–4.9] 2.9 [1.2–6.6] 2.1 [0.9–4.7] <0.001
Albumin to creatinine ratio, mg/g, median (IQR) 7.0 [4.5–13.9] 7.4 [4.8–15.4] 7.0 [4.5–13.8] <0.001
Medications
Antihypertensive medication use, n (%) 10 589 (47.2) 1184 (52.9) 9405 (46.6) <0.001
Statin use, n (%) 5626 (24.9) 571 (25.3) 5055 (24.8) 0.6555
Aspirin use, n (%) 8282 (36.6) 800 (35.3) 7482 (36.7) 0.1947
Antidepressant use, n (%) 2913 (12.9) 600 (26.6) 2313 (11.4) <0.001
Behavioral risk factors
Self-reported smoking, pack years, meanSD 11.320.3 12.522.0 11.220.1 0.0031
Alcohol use, n (%) <0.001
Heavy 964 (4.3) 97 (4.4) 867 (4.3)
Moderate 7595 (34.2) 617 (28.0) 6978 (34.8)
None 13 676 (61.5) 1490 (67.6) 12 186 (60.8)
Continued
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second and third measurements, respectively. The partici-
pants’ average age was 63.4 years, 58.8% were female, 41.7%
were black, 18.6% had diabetes, 32.7% were physically
inactive, and 29.2% were nonadherent to their medication
regimens. Of the participants who completed the initial
baseline scale, patients with elevated depressive symptoms
were more likely to be younger, female, and black; have less
than a high school education; have an income below $20 000
(39.9% versus 14.4%); be uninsured; have higher systolic
blood pressure and total cholesterol; have high-density
lipoprotein; be obese; have diabetes mellitus; have higher
self-reported pack-years; be physically inactive; report med-
ication nonadherence; have higher C-reactive protein levels;
use antihypertensive medications; and, finally, have a pro-
longed corrected QT interval at baseline (Table 1).
Incident Cardiovascular Events
The median follow-up time was 6.9 years. Among participants
with elevated depressive symptoms at any of the 3 assess-
ments, there were 96 (10.7%) CHD events, 81 (12.2%)
strokes, and 94 (13.4%) CVD deaths. In the unadjusted
analyses, the HR for CHD associated with time-varying
depressive symptoms was 1.15 (95% CI 0.93–1.42), which
remained similar after adjusting for demographics, traditional
CVD, and other explanatory behavioral and physiological
factors (Table 2). The unadjusted HR for fatal and nonfatal
stroke with depressive symptoms was 1.35 (95% CI 1.07–
1.70). The adjusted HR (aHR) for fatal and nonfatal stroke was
1.31 (95% CI 1.04–1.67) after controlling for demographic
and traditional CVD risk factors, 1.30 (1.02–1.65) after
adjusting for behavioral factors, and 1.26 (0.99–1.60) after
additionally adjusting for other physiological factors. Time-
varying depressive symptoms were significantly associated
with CVD death in the unadjusted analysis (HR 1.49, 95% CI
1.20–1.85) and remained so after adjusting for demographics
and traditional CVD risk factors (aHR 1.36, 95% CI 1.09–
1.70), behavioral risk factors (aHR 1.35, 95% CI 1.08–1.68),
and other explanatory physiological factors (aHR 1.30, 95% CI
1.04–1.63) (Figure 2).
Assessment of the Potential for Effect
Modification by Race
In additional analyses, we further assessed whether race
moderated the association between depressive symptoms
and CVD. We found that there was no significant interaction
between depressive symptoms and race for any of the
aforementioned outcomes (Table 2). In Model 1, the P value
for the depressive symptoms by race interaction term was
0.21 for CHD, 0.89 for stroke, and 0.77 for CVD death in the
overall models adjusted for all covariates. In the race-
stratified analyses, the HRs for depressive symptoms and
CHD in black and white participants were 1.32 (95% CI 0.99–
1.75; aHR 1.17, 95% CI 0.87–1.57) and 0.97 (95% CI 0.70–
1.34; aHR 0.98, 95% CI 0.70–1.36), respectively.
Discussion
In this large biracial cohort of participants free of CVD and
enrolled in the REGARDS study, we found that proximate
depressive symptoms were associated with a 26% increased
risk of incident stroke and a 30% increased risk of incident
CVD death. Interestingly, depressive symptoms did not confer
increased risk for the outcome of incident CHD. This is one of
few large cohort studies to use multiple measurements of
depressive symptoms and to more definitively clarify that race
does not appear to moderate the relationship between
depressive symptoms and CVD, which was shown inconsis-
tently in the previous literature.
Our study is consistent with prior studies demonstrating
that depressive symptoms confer an increased risk of
stroke,2,10,24 including prior meta-analyses (aHR 1.34, 95% CI
1.17–1.54)10,25 and a prospective study of stroke risk in
middle-aged women with time-varying covariates (adjusted








(n=20 399) P Value†
Physical inactivity, n (%) 7303 (32.7) 997 (44.5) 6306 (31.4) <0.001
Medication nonadherence, n (%) 5916 (29.2) 773 (37.5) 5143 (28.3) <0.001
CES-D indicates Center for Epidemiologic Studies Depression Scale; CVD, cardiovascular disease; IQR, interquartile range; REGARDS, REasons for Geographic And Racial Differences in
Stroke.
*CVD defined as baseline coronary heart disease, stroke, peripheral artery disease, or aortic aneurysm.
†P values from chi-square or student t tests.
‡
“Stroke belt” is defined as the states of Alabama, Arkansas, Louisiana, Mississippi, Tennessee, and the noncoastal regions within the states of North Carolina, South Carolina, and
Georgia. “Stroke buckle” is defined as coastal regions within the states of North Carolina, South Carolina, and Georgia.
§Diabetes is defined as fasting blood glucose ≥126 mL/dL, random glucose >200 mL/dL, or oral hypoglycemic or insulin use.
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literature by accounting for factors such as atrial fibrillation and
left ventricular hypertrophy as well as behavioral factors such
as medication adherence and physical activity, which were
rarely included in prior studies.2,10 In addition, few studies
simultaneously examined the association between depressive
symptoms and both stroke and CHD among participants free
from underlying CVD. A prior European study of predominantly
white men did not adjust for behavioral risk factors or explore
physiological factors and found that baseline depressive
symptoms increased the risk of stroke over 0 to 5 years only
(aHR 1.60, 95% CI 1.1–2.3), whereas only cumulative depres-
sive symptoms led to CHD incidence (1–2 times per case: aHR
1.12, 95% CI 0.7–1.7; 3–4 times: aHR 2.06, 95% CI 1.2–3.7).27
Another study, also conducted in Europe, found that baseline
depressive symptoms conferred an increased risk of CHD (aHR
1.47, 95% CI 1.08–1.99) but not stroke (aHR 0.87, 95% CI
0.57–1.32) in a predominantly young (aged 20–55 years)
nondiverse group of women.7 Our study of diverse middle-aged
to older participants living in the continental United States adds
to the literature by suggesting that elevated depressive
symptoms may be an independent proximal risk factor for
stroke and CVD death but not for CHD, even after controlling
for traditional, behavioral, and other physiological explanatory
factors.
Depressive symptoms have been shown to be associated
with smoking,28 medication noncompliance,29 and physical
inactivity30 as well as diabetes,31 obesity,32 hypertension,33
and inflammation.34 We added to the literature by demon-
strating that these factors and others such as antidepressant
use35 and corrected QT interval36 do not appear to fully
explain the association between depressive symptoms and
incident CVD death and stroke in otherwise healthy persons.
Other unmeasured mediating factors such as heart rate
variability, platelet activation, neurohormonal activation, and
endothelial interaction may play a greater role and explain the
proximate effects on CVD death.37
Our study supports prior literature showing a proximal
association between depressive symptoms and stroke, which
has not been shown to be associated with lifetime or prior
history of depressive symptoms,9 and highlights the urgent
need for early intervention in patients with depressive
symptoms. A recent study showed that collaborative
Table 2. Incident Cardiovascular Events and Death Associated With Time-Varying CES-D Scores*
Time-Varying Categorical CES-D (Score ≥4 vs <4), HR (95% CI)
Overall Black White
CHD n=895 n=377 n=518
Unadjusted 1.15 (0.93–1.42) 1.32 (0.99–1.75) 0.97 (0.70–1.34)
Model 1† 1.16 (0.93–1.43) 1.24 (0.93–1.66) 1.02 (0.74–1.42)
Model 2‡ 1.14 (0.92–1.42) 1.22 (0.91–1.64) 1.00 (0.72–1.39)
Model 3§ 1.11 (0.89–1.38) 1.17 (0.87–1.57) 0.98 (0.70–1.36)
Strokek n=663 n=299 n=364
Unadjusted 1.35 (1.07–1.70)¶ 1.34 (0.97–1.84) 1.29 (0.91–1.82)
Model 1† 1.31 (1.04–1.67)¶ 1.28 (0.93–1.77) 1.30 (0.91–1.85)
Model 2‡ 1.30 (1.02–1.65)¶ 1.28 (0.95–1.77) 1.29 (0.91–1.84)
Model 3§ 1.26 (0.99–1.60)¶ 1.28 (0.92–1.78) 1.23 (0.86–1.76)
CVD death n=702 n=376 n=326
Unadjusted 1.49 (1.20–1.85)¶ 1.41 (1.08–1.86)¶ 1.40 (0.98–1.98)
Model 1† 1.36 (1.09–1.70)¶ 1.35 (1.02–1.80)¶ 1.29 (0.90–1.86)
Model 2‡ 1.35 (1.08–1.68)¶ 1.35 (1.01–1.79)¶ 1.29 (0.90–1.85)
Model 3§ 1.30 (1.04–1.63)¶ 1.28 (0.96–1.71) 1.25 (0.83–1.80)
HR and 95% CI were estimated by Cox proportional hazards regression models. CES-D indicates Center for Epidemiologic Studies Depression Scale; CHD, coronary heart disease; CVD,
cardiovascular disease; HR, hazard ratio.
*Excludes participants with baseline CVD (history of CHD, stroke, peripheral artery disease, aortic aneurism). All participants’ follow-up time ended at the time of the end point, death, or
last follow-up. End of follow-up was December 31, 2012. CES-D measurements taken after an end point or end of follow-up were not considered. Missing data in covariates were imputed.
†Adjusted for demographics: age, sex, region, income, health insurance, education, and traditional CHD risk factors (systolic blood pressure, total cholesterol, high-density lipoprotein
cholesterol, and medication use [aspirin, statins, any antihypertensive medications], body mass index, log of albumin:creatinine ratio, diabetes mellitus).
‡Adjusted for model 1 covariates and behavioral risk factors: pack-years of cigarette smoking, self-reported alcohol use, physical inactivity, medication adherence. All-cause mortality
models also adjusted for self-reported physical health (Short Form 12, Physical Component Summary).
§Adjusted for model 2 covariates and other physiological factors: log of high-sensitivity C-reactive protein, antidepressant use, QT interval corrected for heart rate.
kModels of stroke also adjusted for atrial fibrillation and left ventricular hypertrophy.
¶P<0.05.
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depression care in the primary care setting might lead to
decreased risk of incident CVD events in older patients38;
however, depressive symptoms continue to be suboptimally
recognized, diagnosed, and treated in primary care.39,40
Further research is needed to examine the moderating effect
of depression treatment on incident CVD and to improve
treatment rates in primary care settings.
We did not find an association between depressive
symptoms and our composite outcome of probable myocar-
dial infarction or fatal CHD, although the directionality is
concordant with prior literature.2,3,6,41 Nonetheless, time-
dependent analyses may afford more robust findings (aHR
1.15) compared with the previously published null relationship
between baseline depressive symptoms and incident CHD in
the REGARDS cohort (aHR 0.99, 95% CI 0.66–1.48).42 Prior
research has suggested that cumulative depressive symp-
toms over ≥2 occasions, although subject to selection
bias, are better associated with increased risk of CHD as a
dose-response effect than baseline or proximate symptoms.27
Nonetheless, depressive symptoms may be a better marker of
CHD prognosis in patients with existing heart disease than of
CHD incidence.43
Racial disparities exist for depressive symptom severity,
recognition, and treatment15,44,45 and CVD outcomes.46 Nev-
ertheless, we found that race did not appear to moderate the
association between depressive symptoms and CVD. REGARDS
is a large biracial prospective cohort with expert adjudication of
outcomes, and that may explain why we were able to better
elucidate the potential moderating effect of race shown in prior
studies.11–14 In addition, prior research has suggested that
income may mediate the relationship between race and CVD
outcomes47 and that stress confers increased CVD events
among low-income persons.48 In our analyses, income did not
appear to fully explain the relationship between depressive
symptoms and CVD for either black or white participants.
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Figure 2. Kaplan–Meier graphs of depression and CVD events and deaths on or before December 31, 2012. Kaplan–Meier curves and log-rank
P values for the relationship between depressive symptoms and fatal and nonfatal CHD (A), fatal and nonfatal stroke (B), and CVD death (C).
CES-D indicates Center for Epidemiologic Studies Depression Scale; CHD, coronary heart disease; CVD, cardiovascular disease.
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among race, income, depression, and CVD. Nonetheless, we
demonstrated that early depressive symptom recognition and
treatment should be emphasized, regardless of race.
Our study had several limitations. We were unable to
assess other time-varying covariates, limiting conclusions
regarding mediating effects of behavioral and physiological
conditions. In addition, the use of self-reported covariates
may have led to misclassifcation and reporting biases, which
may have overestimated our results. In addition, our findings
for this biracial US cohort may not be generalizable to other
races and nationalities. We were unable to confirm whether
depressive symptoms were simply a marker of preclinical
CVD, which in turn contributed to CVD death and stroke.27
Finally, we used the short CES-D measurement for depressive
symptoms, but it does not fully measure the breadth of
cognitive and somatic symptoms of depression. Research has
shown that cognitive symptoms are better recognized by
providers but are less likely to predict mortality than somatic
symptoms.49 This may have contributed to the nonsignificant
association between depressive symptoms and CHD,
although the 4-item CES-D has been shown to have adequate
sensitivity and specificity compared with depressive symp-
toms on the 20-item CES-D and has been used to assess
depressive symptoms in prior CVD studies.
In conclusion, time-varying depressive symptoms were
independently associated with incident stroke and CVD death
but not with incident CHD in a large cohort of black and white
adults living in the continental United States, with no
indication that associations were moderated by race. These
findings lend support to the belief that depressive symptoma-
tology is an early modifiable risk factor for CVD. Improving
depressive symptom screening and treatment has the poten-
tial to reduce the burden of incident CVD in the United States.
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